Regulators have lifted the clinical hold on Intellia Therapeutics' MAGNITUDE-2 study, allowing the trial to resume. The company has updated the study protocol, including a higher patient enrollment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results